Ulisses – Scilex Holding

21 Aug

Stephen Ma

September 22, 2025
Posted by Ulisses

Stephen Ma serves as the Chief Financial Officer and Senior Vice President since September 2023. Prior to that, Mr. Ma served as the Company’s Chief Accounting Officer and Vice President of Finance. Mr....

21 Aug

Board of Directors

Alexander Wu, PhD

August 21, 2025
Posted by Ulisses

Yue Alexander Wu is co-founder and CEO of Cothera Bioscience, Inc., a translation medicine and precision therapeutics company. He was previously President, Chief Executive Officer and Chief Strategy Officer of Crown Bioscience International,...

21 Aug

Board of Directors

Stephen Ma

October 2, 2025
Posted by Ulisses

Stephen Ma serves as the Chief Operating Officer, Chief Financial Officer and Senior Vice President since September 2023. Prior to that, Mr. Ma served as the Company’s Chief Accounting Officer and Vice...

21 Aug

Leadership

Henry Ji, PhD

August 21, 2025
Posted by Ulisses

Henry Ji brings 25+ years of experience in the biotechnology and life sciences industry. Dr. Ji is currently serving as Executive Chairman, Chief Executive Officer and President of Scilex Holding Company. Dr....

21 Aug

Leadership

Gigi DeGuzman

October 2, 2025
Posted by Ulisses

Gigi DeGuzman is a seasoned professional with over 25 years of experience in human resources, operations management, facilities management, event planning, executive coordination, and administrative operations. She has played a significant role...

10 Jul

Event Gallery

Gloperba Launch – Nasdaq-2024

June 18, 2025
Posted by Ulisses

Gloperba Launch – Nasdaq-2024

14 Mar

Publications

Decreased Opioid Utilization with Lidocaine Topical System 1.8% Compared to Lidocaine 5% Patch: A Retrospective Claims Analysis

March 14, 2024
Posted by Ulisses

14 Mar

Publications

Retrospective Claims Analysis of Decreased Healthcare Visits with Lidocaine Topical System 1.8% Compared to Lidocaine 5% Patch

March 14, 2024
Posted by Ulisses

05 Mar

Press Release

Scilex Holding Company Announces Closing of $10 Million Bought Deal Offering

March 5, 2024
Posted by Ulisses

PALO ALTO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and...

05 Mar

Press Release

Scilex Holding Company Sets Launch Price of $595 per 150ml bottle of Gloperba®, its First and Only Liquid Oral Version of the Anti-Gout Medicine Colchicine Indicated for the Prophylaxis of Painful Gout Flares in Adults; Expected Plans to Launch in the First Half of 2024

March 5, 2024
Posted by Ulisses

Gloperba® is the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. Gout is a painful arthritic disorder affecting an estimated...